Just days after Sientra might have been celebrating raising $66 million in capital, the breast implant maker finds itself in the cross hairs of health regulators in the United Kingdom and class-action lawyers in the U.S. Sientra’s stock price nosedived more than 52 percent on Sept. 24, just one day after the Goleta-based company completed…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
